Company News
AstraZeneca's latest lung cancer trial fails its primary endpoint
AstraZeneca announced on Tuesday that its ‘PACIFIC-2’ phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.
Vesuvius backs FY expectations despite weaker market conditions, shares slump
Molten metal flow engineer Vesuvius slumped on Tuesday as it said it was still set to meet its full-year expectations, despite weaker market conditions.
Grafton on track to meet FY profit expectations
Building materials distributor and DIY retailer Grafton said on Tuesday that it was on track to deliver full-year operating profit in line with expectations, as it reported an uptick in revenue despite "slightly softer than anticipated" market conditions in September and October.
Babcock backs FY expectations, reinstates dividend
Aerospace and defence firm Babcock backed its full-year expectations on Tuesday, as it reported a rise in first-half revenue and profit, and reinstated its dividend.
Vodafone maintains guidance as first-half earnings fall
Vodafone Group reported a 4. 2% increase in group service revenue in its first half on Tuesday, to €18. 62bn, or 2. 3% excluding Turkey, although overall revenue and profits fell.
Informa lifts full-year guidance, extends share buyback
Events organiser Informa lifted its full-year profit and revenue expectations on Tuesday as it hailed continuing strong growth across its portfolio.
Glencore buys $6.9bn stake in Teck's Elk Valley Resources
Mining and commodities giant Glencore is spending $6. 9bn to buy a 77% stake in Teck Resources' steelmaking coal business in Canada's Rocky Mountains, Elk Valley Resources (EVR).
Imperial delivers flat revenues as volume declines hold back growth
Tobacco and vaping giant Imperial Brands announced that full-year revenues were flat as lower tobacco volumes were offset by strong growth in next-generation products (NGP).